Edition:
United Kingdom

Aerie Pharmaceuticals Inc (AERI.OQ)

AERI.OQ on NASDAQ Stock Exchange Global Market

59.18USD
16 Oct 2018
Change (% chg)

$2.94 (+5.23%)
Prev Close
$56.24
Open
$56.79
Day's High
$59.98
Day's Low
$56.69
Volume
219,661
Avg. Vol
133,375
52-wk High
$74.75
52-wk Low
$47.25

Chart for

About

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02%... (more)

Overall

Beta: 1.06
Market Cap(Mil.): $1,913.33
Shares Outstanding(Mil.): 36.34
Dividend: --
Yield (%): --

Financials

  AERI.OQ Industry Sector
P/E (TTM): -- 86.20 32.69
EPS (TTM): -3.26 -- --
ROI: -51.22 0.73 14.32
ROE: -128.08 1.82 16.04

BRIEF-Aerie Pharmaceuticals Submits NDA To U.S. FDA For Roclatantm

* AERIE PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR ROCLATANTM (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005%

15 May 2018

BRIEF-Aerie Pharmaceuticals Reports Q1 Adjusted Loss Per Share $0.83

* AERIE PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

08 May 2018

BRIEF-Aerie Pharmaceuticals Announces U.S. Launch Of Rhopressa 0.02%

* AERIE PHARMACEUTICALS ANNOUNCES U.S. LAUNCH OF RHOPRESSA® (NETARSUDIL OPHTHALMIC SOLUTION) 0.02%

30 Apr 2018

BRIEF-Aerie Pharmaceuticals CEO Vicente Anido's 2017 Total Compensation Was $10.06 Million

* AERIE PHARMACEUTICALS INC SAYS CEO VICENTE ANIDO'S 2017 TOTAL COMPENSATION WAS $10.06 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2Kn2hS6) Further company coverage:

27 Apr 2018

Earnings vs. Estimates